MarketCap
Facebook
X
Telegram
ENDRA Life Sciences Net Income | NDRA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.03 M | -11.5 M | -10.1 M | -13.2 M | -11.2 M | -11.7 M | -13.3 M | -9.8 M | -5.38 M | -2.78 M | -2.28 M | -2.18 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.18 M | -13.3 M | -8.37 M |
Quarterly Net Income ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.31 M | -1.6 M | -1.23 M | -1.04 M | - | -2.35 M | -2.23 M | -2.78 M | - | -3.1 M | -2.56 M | -2.94 M | - | -3.44 M | -3.59 M | -2.86 M | - | -2.66 M | -3.2 M | -2.27 M | - | -3.26 M | -2.89 M | -3.32 M | - | -3.41 M | -2.33 M | -2.75 M | - | -2.76 M | -1.85 M | -2.83 M | - | -909 K | -1.43 M | -742 K | - | -978 K | -729 K | -379 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -379 K | -3.59 M | -2.25 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K |  USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B |  Niderland |
 |
Centogene N.V.
CNTG
|
-35.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 6.98 | 1.51 % | $ 27.8 M |  Israel |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 293.35 | 0.54 % | $ 14.5 B | USA |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 163.58 | 2.34 % | $ 12.8 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
2.92 M | $ 14.51 | 1.61 % | $ 493 M | Israel |
 |
Celcuity
CELC
|
-177 M | $ 96.43 | 0.24 % | $ 4.51 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M | Israel |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 356.23 | 0.66 % | $ 28 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-366 M | $ 3.23 | 1.57 % | $ 299 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-12 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-811 M | - | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 21.25 | 6.2 % | $ 476 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
OPKO Health
OPK
|
-226 B | $ 1.61 | 11.18 % | $ 1.21 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.3 | 3.13 % | $ 390 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 16.83 | 0.6 % | $ 1.5 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 239.4 | 2.07 % | $ 26.6 B | USA |
 |
DexCom
DXCM
|
836 M | $ 89.71 | 0.02 % | $ 35 B | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
-13.8 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
23.6 M | - | -16.95 % | $ 1.54 M | USA |
 |
T2 Biosystems
TTOO
|
-50.1 M | - | -39.35 % | $ 313 K | USA |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 3.05 | 0.64 % | $ 99 K | USA |
 |
Neuronetics
STIM
|
-39 M | $ 2.72 | 0.18 % | $ 179 M | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Meridian Bioscience
VIVO
|
42.5 M | - | - | $ 1.49 B | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 271.62 | 2.95 % | $ 46.7 B | USA |
 |
Surmodics
SRDX
|
-11.5 M | - | - | $ 608 M | USA |
 |
Quidel Corporation
QDEL
|
810 M | $ 13.93 | 1.45 % | $ 587 M | USA |